Stock Library / UTHR

UTHR Unclassified Latest YouTube: Q2 2026 Published 2026-08-05

UTHR

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

United Therapeutics (UTHR): $7.27 Beat Consensus. Operating Income Fell 9%.

Published 2026-08-05

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-05

Podcast available

Yes

Current price

$532.94

+13.93 (+2.68%)

Trailing / Forward P/E

19.09x

Forward: 17.00x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

-1.9%

Earnings: 13.4%

Margins

42.2% op

Gross: 86.1% · Net: 41.6%

Balance sheet

5.73x current

Debt / Equity: —

52-week range / Beta

$292.34 - $609.35

Beta: —

Analyst target

$663.23

Upside: 24.4%

Cash / shareholder return

2.12% FCF yield

Dividend yield: —

Company context

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Employees: —

Price to book: 3.63x

Return on equity: 19.3%

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Price chart

Market context for UTHR

Competitive view

UTHR vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

UTHR latest YouTube video thumbnail

UTHR

UTHR

YouTube Spotify Podbean

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Palantir Technologies latest YouTube video thumbnail

Palantir Technologies

PLTR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

UTHR

$26.54B

UTHR

SSNC

$18.73B

SS&C Technologies Holdings Inc.

PLTR

$374.68B

Palantir Technologies

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

UTHR

19.1x

UTHR

SSNC

22.9x

SS&C Technologies Holdings Inc.

PLTR

175.2x

Palantir Technologies

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

UTHR

17.0x

UTHR

SSNC

10.3x

SS&C Technologies Holdings Inc.

PLTR

68.9x

Palantir Technologies

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

UTHR

-1.9%

UTHR

SSNC

10.3%

SS&C Technologies Holdings Inc.

PLTR

92.8%

Palantir Technologies

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

UTHR

13.4%

UTHR

SSNC

34.7%

SS&C Technologies Holdings Inc.

PLTR

215.4%

Palantir Technologies

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

UTHR

42.2%

UTHR

SSNC

24.6%

SS&C Technologies Holdings Inc.

PLTR

47.1%

Palantir Technologies

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

UTHR

86.1%

UTHR

SSNC

48.1%

SS&C Technologies Holdings Inc.

PLTR

84.8%

Palantir Technologies

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

UTHR

41.6%

UTHR

SSNC

13.2%

SS&C Technologies Holdings Inc.

PLTR

49.0%

Palantir Technologies

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

UTHR

19.3%

UTHR

SSNC

12.6%

SS&C Technologies Holdings Inc.

PLTR

38.1%

Palantir Technologies

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

UTHR

2.1%

UTHR

SSNC

7.0%

SS&C Technologies Holdings Inc.

PLTR

0.6%

Palantir Technologies

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

UTHR

—

UTHR

SSNC

115.90x

SS&C Technologies Holdings Inc.

PLTR

2.14x

Palantir Technologies

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

UTHR

5.73x

UTHR

SSNC

1.06x

SS&C Technologies Holdings Inc.

PLTR

7.23x

Palantir Technologies

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

UTHR

—

UTHR

SSNC

1.09

SS&C Technologies Holdings Inc.

PLTR

1.56

Palantir Technologies

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

UTHR

—

UTHR

SSNC

1.4%

SS&C Technologies Holdings Inc.

PLTR

—

Palantir Technologies

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

UTHR

24.4%

UTHR

SSNC

15.6%

SS&C Technologies Holdings Inc.

PLTR

21.1%

Palantir Technologies

Related research

Non-quarter videos featuring UTHR

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-05

UTHR beat by 6% — and operating income FELL 9% #shorts #stocks

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for UTHR

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-05

Published youtube podcast complete

United Therapeutics (UTHR): $7.27 Beat Consensus. Operating Income Fell 9%.

Quarterly earnings-analysis entry for UTHR. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music